BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33628731)

  • 1.
    Molica M; Mazzone C; Niscola P; de Fabritiis P
    Front Oncol; 2020; 10():610820. PubMed ID: 33628731
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
    Barbosa K; Li S; Adams PD; Deshpande AJ
    Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
    Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
    Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Shin DY
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.
    Testa U; Castelli G; Pelosi E
    Mediterr J Hematol Infect Dis; 2023; 15(1):e2023038. PubMed ID: 37435040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet Horizons: Assessing the Challenges in the Treatment of
    Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Diamantopoulos PΤ
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
    Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
    Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting
    Granowicz EM; Jonas BA
    Onco Targets Ther; 2022; 15():423-436. PubMed ID: 35479302
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
    Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
    Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
    Haferlach C; Dicker F; Herholz H; Schnittger S; Kern W; Haferlach T
    Leukemia; 2008 Aug; 22(8):1539-41. PubMed ID: 18528419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and new treatment approaches in TP53 mutated AML.
    Hunter AM; Sallman DA
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
    Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
    J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
    Asghari H; Talati C
    Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.